Susceptibility of the Acinetobacter calcoaceticus–A. baumannii complex to imipenem, meropenem, sulbactam and colistin

Dı́ez, Ana Isabel Dueñas; Pérez, María Jesús Verdú; Bouza, José Marı́a Eiros; Gómez, Ana Almaraz; Rodriguez, P.; Gómez, Mauricio Rojas; Domingo, Antonio Orduña; Rodríguez‐Torres, A

doi:10.1016/j.ijantimicag.2003.09.026

Cited by 25 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The significant finding in their study was that eight (3.5%) isolates were resistant to both colistin and tigecycline. [32] Various authors have reported the resistance rate to colistin between 1.8% and 2%,[3334] while resistance to tigecycline varies from being nonexistent to 66%. [3536] We did not find any Acinetobacter isolate being resistant to colistin, which may be due to its selective use only in case of carbapenem-resistant gram-negative bacteria.…”

Section: Discussionmentioning

confidence: 99%

Frequency, risk factors, and antibiogram of Acinetobacter species isolated from various clinical samples in a tertiary care hospital in Odisha, India

et al. 2013

View full text Add to dashboard Cite

Background:For the past two decades, Acinetobacter spp. have emerged as an important pathogen globally in various infections.Objectives:This study was conducted to determine the frequency, risk factors, and antibiotic resistance pattern of Acinetobacter spp. from various clinical samples.Materials and Methods:This retrospective, hospital record–based, cross-sectional study included a total of 8749 clinical samples collected from patients at a tertiary care hospital in Odisha, India from July 2010 to December 2012. The samples were processed and identified by standard protocol. The Acinetobacter isolates were tested for antibiotic resistance by Kirby-Bauer disk diffusion method [according to the Clinical and Laboratory Standards Institute (CLSI) guidelines].Results:From 8749 clinical samples, 4589 (52.5%) yielded significant growth and only 137 (3%, 137/4589) Acinetobacter spp. were isolated. Maximum (56.9%) isolates were obtained from pus/swab, followed by blood (13.1%) and urine (12.4%). Elderly age, being inpatients, longer duration of stay in the hospital, associated co-morbidity, and invasive procedure were found to be significant risk factors in the setup investigated (P is less than 0.05). Out of 137 isolates, 75 (54.7%) were resistant to more than three classes of antibiotics (multidrug resistant) and 8 (5.8%) were resistant to all commonly used antibiotics (pan-drug resistant). Majority of the isolates were sensitive to imipenem, meropenem, and piperacillin/tazobactam, and showed resistance rates of 19%, 22%, and 23%, respectively. All eight pan-drug resistant isolates were 100% sensitive to colistin.Conclusion:This hospital-based epidemiological data will help to implement better infection control strategies and improve the knowledge of antibiotic resistance patterns in our region.

show abstract

Section: Discussionmentioning

confidence: 99%

Frequency, risk factors, and antibiogram of Acinetobacter species isolated from various clinical samples in a tertiary care hospital in Odisha, India

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Figure 2 shows the sulbactam CSF concentration-time curve in the group. The sulbactam concentration did not reach the level of MIC 50 of 8 mg/L for Acinetobacter baumannii [ 8 , 9 ].The relationship between cefoperazone concentrations at different time points and MIC 50 was presented in Figure 3 . There are 51.6% (32/62) of the cefoperazone concentrations at different time points over MIC 50 .…”

Section: Resultsmentioning

confidence: 99%

Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy

Wang

Chen

et al. 2015

BMC Anesthesiol

View full text Add to dashboard Cite

BackgroundTo identify changes in cefoperazone/sulbactam penetration into cerebrospinal fluid (CSF) after craniotomy and to investigate preliminarily whether cefoperazone/sulbactam CSF concentration can reach therapeutic level when administered intravenously after neurosurgical operation.MethodsNeurosurgical patients with an indwelling ventricular drainage pipe who received prophylactic cefoperazone/sulbactam for the treatment of intracranial infection were received a cefoperazone/sulbactam 2:1, 3.0-g infusion for 3 hours every 6 hours for 24 h. Venous blood and CSF specimens were collected to determine cefoperazone/sulbactam concentrations.ResultsThe cefoperazone and sulbactam concentrations in serum were highest at the second hour (237.54±336.72 mg/L and 66.52±80.38 mg/L, respectively) and then decreased. The cefoperazone and sulbactam concentrations in CSF were highest at the 4th hour (39.22±75.55 mg/L and 6.24±8.35 mg/L, respectively) and then decreased. CSF penetration measured by the ratio of peak concentrations (CSF/serum) was 8.6%±7.2% for cefoperazone and 13.5%±11.9% for sulbactam, CSF penetration measured by the ratio of trough concentrations (CSF/serum) was 13.4%±5.3% for cefoperazone and 106.5%±87.5% for sulbactam. CSF penetration represented by the ratio of area under the curve (AUC) of CSF and serum was 14.5% for cefoperazone and 22.6% for sulbactam. Neurosurgical impairment of the blood–brain barrier may improve the CSF penetration of these drugs, but it is difficult to reach the MIC90 of resistant bacteria. If single intravenous administration time was extended to 3 hours, the serum concentrations of drugs were able to meet the PK/PD standard (T> MIC%> 50%) for treating common, highly resistant bacteria.ConclusionsThe CSF penetration of cefoperazone/sulbactam may be enhanced after neurosurgical impairment of the blood–brain barrier. This study is a pilot research of cefoperazone/sulbactam using in neurosurgical individuals, However, it needs to be confirmed by further large-scale studies.

show abstract

The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest® and time-kill assay

Pankey

Ashcraft

2009

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

Susceptibility of the Acinetobacter calcoaceticus–A. baumannii complex to imipenem, meropenem, sulbactam and colistin

Cited by 25 publications

References 39 publications

Frequency, risk factors, and antibiogram of Acinetobacter species isolated from various clinical samples in a tertiary care hospital in Odisha, India

Frequency, risk factors, and antibiogram of Acinetobacter species isolated from various clinical samples in a tertiary care hospital in Odisha, India

Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy

The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest® and time-kill assay

Contact Info

Product

Resources

About